174 related articles for article (PubMed ID: 25748298)
1. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.
Anforth R; Menzies A; Byth K; Carlos G; Chou S; Sharma R; Scolyer RA; Kefford R; Long GV; Fernandez-Peñas P
J Am Acad Dermatol; 2015 May; 72(5):809-15.e1. PubMed ID: 25748298
[TBL] [Abstract][Full Text] [Related]
2. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
3. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.
Anforth R; Blumetti TC; Clements A; Kefford R; Long GV; Fernandez-Peñas P
Br J Dermatol; 2013 Dec; 169(6):1310-3. PubMed ID: 23870055
[TBL] [Abstract][Full Text] [Related]
4. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity.
Adelmann CH; Ching G; Du L; Saporito RC; Bansal V; Pence LJ; Liang R; Lee W; Tsai KY
Oncotarget; 2016 May; 7(21):30453-60. PubMed ID: 27028853
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.
Ali M; Anforth R; Senetiner F; Carlos G; Fernandez-Penas P
Exp Dermatol; 2016 May; 25(5):394-5. PubMed ID: 26896751
[No Abstract] [Full Text] [Related]
6. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
7. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
8. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
[TBL] [Abstract][Full Text] [Related]
9. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
10. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Falchook GS; Long GV; Kurzrock R; Kim KB; Arkenau TH; Brown MP; Hamid O; Infante JR; Millward M; Pavlick AC; O'Day SJ; Blackman SC; Curtis CM; Lebowitz P; Ma B; Ouellet D; Kefford RF
Lancet; 2012 May; 379(9829):1893-901. PubMed ID: 22608338
[TBL] [Abstract][Full Text] [Related]
11. The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark.
Li H; Pedersen L; Nørgaard M; Ulrichsen SP; Thygesen SK; Nelson JJ
BMC Cancer; 2016 May; 16():295. PubMed ID: 27141983
[TBL] [Abstract][Full Text] [Related]
12. Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.
Amaravadi RK; Hamilton KE; Ma X; Piao S; Portillo AD; Nathanson KL; Carlino MS; Long GV; Puzanov I; Xu X; Morrissette JJ; Tsai KY; Flaherty KT; Sosman JA; Goodman GR; McArthur GA; Rustgi AK; Metz DC; Schuchter LM; Chapman PB; Sepulveda AR
Clin Cancer Res; 2015 Dec; 21(23):5215-21. PubMed ID: 26202952
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
14. Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.
Vigarios E; Lamant L; Delord JP; Fricain JC; Chevreau C; Barrés B; Gomez-Roca C; Boulanger M; Sibaud V
Br J Dermatol; 2015 Jun; 172(6):1680-1682. PubMed ID: 25495246
[No Abstract] [Full Text] [Related]
15. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P
Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352
[TBL] [Abstract][Full Text] [Related]
16. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
Escuin-Ordinas H; Atefi M; Fu Y; Cass A; Ng C; Huang RR; Yashar S; Comin-Anduix B; Avramis E; Cochran AJ; Marais R; Lo RS; Graeber TG; Herschman HR; Ribas A
Mol Oncol; 2014 Mar; 8(2):250-60. PubMed ID: 24345644
[TBL] [Abstract][Full Text] [Related]
17. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma.
Ramani NS; Curry JL; Kapil J; Rapini RP; Tetzlaff MT; Prieto VG; Torres-Cabala CA
Am J Dermatopathol; 2015 Aug; 37(8):e96-9. PubMed ID: 25839886
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
Zhao CY; Hwang SJE; Anforth R; Carlos G; Chou S; Carlino M; Fernández-Peñas P
J Immunother; 2018 Sep; 41(7):343-349. PubMed ID: 29939876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]